Innovations in drug development have led to highly targeted therapies for cancer and autoimmune disorders that can be administered subcutaneously, offering a faster and less invasive administration mode to patients. However, challenges like resistance to change or side effects affect adoption. To address this, pharmaceutical companies can leverage digital health solutions to guide patients through self-administration, symptom management, and communication with their healthcare providers, to improve access to valuable therapies. In 2024, Aptar Digital Health and Gerresheimer partnered to develop tailored solutions to support patients and healthcare providers in subcutaneous cancer therapy administration and management. The partnership brings Aptar Digital Health’s expertise in developing software as a medical device with Gerresheimer’s innovative on-body device for subcutaneous delivery of large biologic molecules, Gx SensAir®.
Learn more about how both companies join forces to enhance the patient experiences in the article below:
